SLC5A2 and diabetes mellitus: New users of SGLT-2 inhibitors were younger (56.2 vs 61.9 years), and more likely to be male (53.1% v 51.6%) and have severe diabetes (1.1 vs 0.8 score) and comorbidities of eye disease (11.4% vs 6.6%) compared with users of first-line medications.